UCB : S.A. - Acquisitions of own shares and Disposals of own shares

In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, UCB SA/NV ('UCB' or the 'Company) (Euronext Brussels: UCB) hereby discloses certain information in relation to its Share Repurchase Program 2020.

Under this program, UCB has requested a financial intermediary to repurchase up to 1.2 million UCB shares on its behalf under the terms of an initial discretionary mandate agreement with validity until 15 June 2020, effective as from 25 March 2020, to cover current and future obligations under UCB's Long Term Incentive Plans for its personnel.

Contact:

Antje Witte

Tel: [phone]

Email: [e-mail]

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 7 500 people in approximately 40 countries, the company generated revenue of EUR 4.9 billion in 2019. UCB is listed on Euronext Brussels (symbol: UCB).

(C) 2020 Electronic News Publishing, source ENP Newswire